Drug intelligence / Profile preview

Tongxuan Lifei Pill

Development stage: Unknown
Lead developer: Shandong Wohua Pharmaceutical
Administration: Oral

Overview

Tongxuan Lifei Pill is a traditional Chinese medicine (TCM) formulation developed and marketed by Shandong Wohua Pharmaceutical Polytron Technologies. It is primarily indicated for the treatment of respiratory disorders, specifically the common cold (categorized as "wind-cold" in TCM) and associated symptoms such as cough, nasal congestion, and headache. As a TCM product, it consists of a complex mixture of herbal ingredients that function by inducing diaphoresis to dispel cold, ventilating the lungs, and resolving phlegm. The drug is administered orally in a pill formulation and is part of Shandong Wohua's established portfolio of approved TCM products in China.

Brand names: Tongxuan Lifei Pill
Other names: 通宣理肺丸Tongxuan Lifei Wan

Beyond the preview

Go deeper on Tongxuan Lifei Pill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongxuan Lifei Pill.

Explore the full profile